VEGFA and age-related macular degeneration: During the last decade, in addition to surgery, intravitreal injections of anti-VEGF monoclonal antibodies or gene therapy products have become the standard of care for CNV and have contributed to, and importantly reduced, AMD-related blindness [4,5,7,16,17].